Innovent Biologics Stock News

Spero Therapeutics has licensed rights outside Greater China to develop and commercialize Innovent Biologics' ​experimental autoimmune disease treatment in a deal worth ‌up to about $1.1 billion, the companies said on Tuesday.

Innovent Biologics ​has entered ‌into an agreement that ​grants ​it sole commercialization ⁠rights for ​Eli Lilly's ​breast cancer drug Verzenios in ​mainland ​China, the Chinese drugmaker ‌said ⁠Tuesday.

Pfizer's GLP-1 ​drug Ecnoglutide ‌and Innovent Biologics' ​mazdutide injection ​have passed a ⁠preliminary ​review to ​be potentially included in China's ​basic ​medical insurance drug catalogue, ‌a ⁠a list published by ​the ​National ⁠Healthcare Security Administration ​showed ​on ⁠Monday.

SAN FRANCISCO and SUZHOU, China, June 24, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin has...

SAN FRANCISCO and SUZHOU, China, June 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chi...

SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the international multi-center Phase 3 clini...